Study reveals how a blood biomarker tracks response to lecanemab in early Alzheimer's disease

Alzheimer's illness (AD) is simply a progressive neurodegenerative upset characterized by changes involving amyloid-beta and tau proteins successful the brain. Lecanemab is an anti-amyloid therapy approved for radical with aboriginal AD that has been shown to dilatory illness progression. However, attraction responses tin alteration among individuals, creating a request for accessible ways to show biologic changes during therapy.